GSK Enters Agreement to Acquire IDRx, Inc. - MarketScreener

2 days ago · Under the terms of the agreement, GSK will acquire one hundred percent (100%) of the outstanding equity interests (including all options and other incentive equity) in IDRx for up …

100%
OFF

GSK Enters Agreement To Acquire IDRx, Inc. - MarketScreener

2 weeks from now

2 days ago · Under the terms of the agreement, GSK will acquire one hundred percent (100%) of the outstanding equity interests (including all options and other incentive equity) in IDRx for up …

marketscreener.com

100%
OFF

GSK Enters Agreement To Acquire IDRx, Inc.

2 weeks from now

3 days ago · Under the terms of the agreement, GSK will acquire one hundred percent (100%) of the outstanding equity interests (including all options and other incentive equity) in IDRx for up …

gsk.com

$1
OFF

GSK Plc Entered Into An Agreement To Acquire IDRX, Inc. For ...

2 weeks from now

2 days ago · GSK plc (LSE:GSK) entered into an agreement to acquire IDRX, Inc. for approximately $1.2 billion on January 13, 2025. Under the terms of the agreement, GSK will …

marketscreener.com

$1
OFF

GSK Is Said To Be Nearing $1B Deal To Acquire U.S. Biotech IDRx

2 weeks from now

British pharma giant GSK (NYSE:GSK) is closing in on a $1B buyout deal to acquire IDRx, a U.S. biotech focused on developing drugs for rare gastrointestinal tumors, The Financial Times …

msn.com

100%
OFF

2025-01-13 | GSK Enters Agreement To Acquire IDRx, Inc.

2 weeks from now

3 days ago · Under the terms of the agreement, GSK will acquire one hundred percent (100%) of the outstanding equity interests (including all options and other incentive equity) in IDRx for up …

stockhouse.com

100%
OFF

GSK Enters Agreement To Acquire IDRx, Inc. – IDRx

2 weeks from now

3 days ago · Under the terms of the agreement, GSK will acquire one hundred percent (100%) of the outstanding equity interests (including all options and other incentive equity) in IDRx for up …

idrx.com

$1.15
OFF

GSK Acquiring US-Based IDRx For Up To $1.15 Billion

2 weeks from now

2 days ago · -- GSK has agreed to acquire Boston-based IDRx for up to $1.15 billion as the British drugmaker looks to expand its gastrointestinal cancer portfolio, the companies said Monday. ...

marketscreener.com

100%
OFF

GSK Enters Agreement To Acquire IDRx, Inc. | Company …

2 weeks from now

3 days ago · Under the terms of the agreement, GSK will acquire one hundred percent (100%) of the outstanding equity interests (including all options and other incentive equity) in IDRx for up …

investegate.co.uk

100%
OFF

GSK Enters Agreement To Acquire IDRx, Inc. | Morningstar

2 weeks from now

3 days ago · Under the terms of the agreement, GSK will acquire one hundred percent (100%) of the outstanding equity interests (including all options and other incentive equity) in IDRx for up …

morningstar.com

100%
OFF

GSK Enters Agreement To Acquire IDRx, Inc. | Regulatory News

2 weeks from now

2 days ago · Under the terms of the agreement, GSK will acquire one hundred percent (100%) of the outstanding equity interests (including all options and other incentive equity) in IDRx for up …

lse.co.uk

$1.15
OFF

GSK Enters Agreement To Acquire IDRx, Inc. | GSK - MarketScreener

2 weeks from now

2 days ago · - Acquisition adds to GSK's growing portfolio in gastrointestinal (GI) cancers - GSK to pay up to $1.15 billion. London, UK-- GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) …

marketscreener.com

$1
OFF

GSK Nearing Deal To Acquire US Biotech IDRx For Up To $1 Billion

2 weeks from now

Jan 8, 2025 · MarketScreener tools. Stock Screener; iPhone App; Expert tools. Stock Screener PRO; Portfolio Creator; Event Screener; Dynamic Chart; Earnings Calendar; ... GSK: …

marketscreener.com

$1
OFF

GSK Nears Deal To Acquire US Biotech IDRx For Up To $1 Billion

2 weeks from now

Jan 8, 2025 · -- GSK is in advanced discussions to acquire closely held US biotech company IDRx for up to $1 billion, the Financial Times reported Wednesday, citing people close to the …

marketscreener.com

100%
OFF

GSK Enters Agreement To Acquire IDRx, Inc. - Lelezard.com

2 weeks from now

2 days ago · Under the terms of the agreement, GSK will acquire one hundred percent (100%) of the outstanding equity interests (including all options and other incentive equity) in IDRx for up …

lelezard.com

FAQs about GSK Enters Agreement to Acquire IDRx, Inc. - MarketScreener Coupon?

Will GSK acquire idrx?

PLYMOUTH, Mass., January 13, 2025 -- (BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based, clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for the treatment of GIST. ...

How much will GSK pay for idrx-42?

Under the agreement, GSK will pay $1 billion upfront, with potential for an additional $150 million success-based regulatory approval milestone payment. The acquisition includes lead molecule, IDRX-42, a highly selective KIT TKI being developed as a first- and second-line therapy for the treatment of GIST. ...

Could GSK & idrx opt out of a biotech deal?

As discussions continue, the people added that GSK (NYSE: GSK) and IDRx could opt out of the deal, or the company will attract a new buyer. A clinical-stage biotech founded in 2022, IDRx has private equity firm Blackstone (BL) and venture capital firms Andreessen Horowitz and RA Capital among its notable investors. ...

Who owns idrx-42?

A clinical-stage biotech founded in 2022, IDRx has private equity firm Blackstone (BL) and venture capital firms Andreessen Horowitz and RA Capital among its notable investors. Its initial product candidate, IDRX-42, targets gastrointestinal stromal tumor (GIST), a GIT cancer that affects an estimated 4,000–6,000 Americans every year. ...

Is idrx-42 a second-line option in GIST?

The U.S. FDA has granted orphan drug designation and fast-track designation for IDRX-42 in GIST. A Phase 1/1b open-label Phase 1 trial for the oral candidate is currently underway and initial data from the study has demonstrated IDRX-42's potential as a second-line option in GIST, according to IDRx. ...

Is idrx-42 effective in patients with advanced GIST?

Updated clinical data from StrateGIST 1, an ongoing phase I/Ib trial of IDRX-42 in patients with advanced GIST, were presented in an oral presentation at the Connective Tissue Oncology Society (CTOS) 2024 Annual Meeting. These data show promising anti-tumour activity of IDRX-42 in patients with advanced GIST with a manageable safety profile. ...